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Although cytokine immunotherapy has been regarded for many
years as one of the most promising strategies to achieve long-term
control of solid tumours, clinical results have been to a large extent
disappointing. This is due both to the high toxicity of systemically
administered cytokines and to the heterogeneity and unpre-
dictability of clinical responses. Recent advances suggest that
the ability of interleukin-2 (IL-2) to generate and/or amplify an
effective immune response relies on its intratumoral, rather than
systemic, availability (Forni et al, 1988; Sitkovsky and Paul,
1988). IL-2 delivery at the tumour site is effective in providing a
‘local help’ for the induction of anti-tumour cytotoxic T lympho-
cytes (CTLs) (Fearon et al, 1990). By acting in a paracrine fashion,
intratumoral IL-2 bypasses the requirement for T-helper cells that
are paralysed by the lack of adequate costimulation or by the pres-
ence of tumour-derived immunosuppressive factors (Fearon et al,
1990; Guarini et al, 1997). Moreover, local IL-2 delivery circum-
vents the toxicity elicited by the systemic administration of high
cytokine doses.
Effective gene-engineering techniques make cancer cells
capable of releasing a cytokine within a growing tumour. Over the
last few years, the successful insertion of several cytokine genes
into murine and human cancer cells has been documented. Studies
in mice have shown that IL-2 release by the engineered neoplastic
cell leads to tumour rejection and specific CTL generation, and
confers an immunological memory against subsequent challenges
of the parental tumour (Fearon et al, 1990; Musiani et al, 1997).
Moreover, vaccination with IL-2 transduced tumour cells has
proven effective in the ‘cure’ of established parental tumours
(Musiani et al, 1997). Human cancer cells of different origin
(melanoma, renal cell carcinoma, lung carcinoma, acute
leukaemia) have also been successfully transduced with different
cytokine genes (Gansbacher et al, 1992; Gastl et al, 1992; Alosco
et al, 1993; Cignetti et al, 1994; Hathorn et al, 1994; Guarini et al,
1995, 1996, 1997; Meazza et al, 1996; Stein et al, 1996), and ther-
apeutic vaccination trials with IL-2 engineered tumour cell lines
have been activated in advanced melanoma and renal cell carci-
noma patients (Dranoff and Mulligan, 1995).
Transitional cell carcinoma of the bladder is the third most
common cancer in males in Western countries. Superficial bladder
cancer is responsive to intravesical treatment with bacillus
Calmette–Guérin (BCG), which potentiates host immune
responses and induces significant urinary IL-2 levels (Lum and
Torti, 1995). Regional (intra-arterial or intravesical) recombinant
IL-2 (rIL-2) administration is also effective in inducing tumour
regression, by means of increasing an inflammatory reaction and
activating an immune response at the tumour site (Velotti et al,
1994; Lum and Torti, 1995). Studies in a mouse tumour model of
bladder cancer have recently shown that irradiated IL-2 gene-
modified MBT-2 tumour cells cure a substantial proportion of
mice from a significant burden of parental tumour implanted
orthotopically into the bladder wall (Connor et al, 1993). Cured
mice are capable of rejecting a subsequent challenge with a highly
tumorigenic dose of parental unmodified MBT-2 cells, thus
suggesting the induction of a protective immunological memory.
These clinical and experimental findings suggest that IL-2 gene
therapy may be a very effective therapeutic approach for bladder
cancer. Surprisingly, no data have been reported on human bladder
carcinoma cells, so far. Therefore, in this preclinical study we
tested the feasibility of transducing human bladder cancer cells
with the human IL-2 gene and analysed the phenotypic and func-
tional characteristics of the transduced cells.
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Summary Transitional cell carcinoma of the bladder is one of the human cancers most responsive to immunotherapy, and local interleukin-2
(IL-2) production appears to be an important requirement for immunotherapy to be effective. In this study, we engineered two human bladder
cancer cell lines (RT112 and EJ) to constitutively release human IL-2 by retroviral vector-mediated gene transfer. Following infection and
selection, stable and consistent production of biologically active IL-2 was demonstrated at both the mRNA and the protein level. Morphology,
in vitro growth rate and proliferation, as well as other cytokine gene mRNA or membrane adhesion receptor expression, were not altered in
IL-2 transduced cells as compared to their parental or control vector-infected counterparts. Moreover, IL-2 engineered cells lost their
tumorigenicity into nu/nu mice and the mechanism of rejection appeared to involve multiple host effector cell populations, among which a
prominent role was played by neutrophils and radiosensitive cells. These findings may offer support to the development of an IL-2-based gene
therapy approach to human bladder cancer.
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Cell lines
The human transitional bladder carcinoma cell lines RT112 and EJ
(also known as MGH-U1) were kindly provided by Dr Prescott
(Department of Surgery/Urology, Western General Hospital,
Edinburgh, UK). Both cell lines were cultured in Roswell Park
Memorial Institute (RPMI)-1640 medium (Gibco, Paisley, UK)
supplemented with 10% fetal calf serum (FCS, Gibco), 50 U/ml
penicillin, 50 mg/ml streptomycin and 2 mM glutamine (Flow
Laboratories, Irvine, UK).
IL-2 gene transduction
IL-2 cDNA cloned from human peripheral blood lymphocytes was
inserted into the Moloney murine leukaemia virus-derived retro-
viral vector LXSN containing the selectable marker NeoR, and
producer cells were obtained by transfection as previously
described (Dusty Miller and Rosman, 1989; Melani et al, 1994).
RT112 or EJ cells (106) were exposed to undiluted viral super-
natant for 3 h in the presence of 8 mg ml–1 of polybrene, and
selected in 0.8 mg ml–1 G418 (Sigma Chemical Co., St Louis, MO,
USA). RT112 or EJ cells infected with the LXSN vector were used
as a transfection control in all experiments.
Proliferation assay
Five thousand cells/well were seeded in flat bottom 96-well
microplates and cultured in triplicates under different conditions
(see Figure 2). Cells were labelled with 74 kBq of [3H]TdR
(methyl-3H-thymidine, 185 GBq mmol, 5 Ci mmol–1, Amersham
Life Sciences, Milano, Italy)/well, harvested 18 h later, and
[3H]TdR uptake was determined by liquid scintillation spectrom-
etry and expressed as total counts per minute (cpm).
To measure released IL-2 biological activity, 2.5 ´ 105 infected
cells were seeded in 3.5 cm plates, cultured for 48 h, and the super-
natants were then harvested. IL-2 biological activity in the super-
natants was assessed by measuring the growth of either an
IL-2-dependent murine T-cell line (CTLL) or a preparation of
human phytohaemagglutinin (PHA)-stimulated T-cell blasts from
healthy donors in a proliferation assay. IL-2 activity in the super-
natants was expressed as International Units (IU): the titer that
gave 50% of maximal [3H]TdR incorporation was determined by a
probit analysis computer program (Sette et al, 1986). Our labora-
tory standard was calibrated against that of the Biological
Response Modifier Program (National Cancer Institute, Bethesda,
MD, USA) reference reagent human IL-2 (lot ISDP-841).
Cytokine mRNA expression
Total RNA was extracted by the method of Chomczynski and
Sacchi (1987). Reverse transcription (RT) was performed on 5 mg
of total RNA; the reaction mixture included: 1 mg oligo-dT, 1 mM
deoxyribonucleotides (dNTPs), 5 ml of the 10 ´ RT buffer [200 mM
Tris-HCl pH 8.8, 500 mM KCl, 1 mg ml–1 bovine serum albumin
(BSA)], 25 mM magnesium chloride (MgCl2), 40 U Rnasin and
100 U reverse transcriptase Superscript Rnase H (Gibco).
Polymerase chain reaction (PCR) amplification was performed in
a final volume of 50 ml containing 1 ml of cDNA, 2.5 ml of each
primer at a concentration of 20 mM, 3 ml of 2.5 mM dNTPs, 3 ml of
25 mM MgCl2, 5 ml of 10 ´ PCR reaction buffer (200 mM Tris-HCl
pH 8.4, 500 mM KCl) and 0.5 ml of 5 U ml–1 Taq polymerase
(Gibco). The following temperature conditions were used for the
reactions: 2 min initial denaturation at 94°C, then 32 cycles of:
1 min denaturation at 94°C; annealing at 60°C (IL-2), 55°C (IL-6),
63°C [tumour necrosis factor-a (TNF-a) and b2-microglobulin
(b2m), or 59°C (IL-4, transforming growth factor-b (TGF-b) and
granulocyte-macrophage colony-stimulating factor (GM-CSF)];
synthesis for 1 min at 72°C. Specific primers were synthesized on
the basis of published sequences. PCR products were elec-
trophoresed on a 2% agarose gel in Tris–borate–EDTA buffer.
Gels were then stained with ethidium bromide and photographed.
Immunofluorescence and cytofluorimetric analysis
The following commercially available mouse monoclonal anti-
bodies (mAbs) were used: anti-a1 (T Cell Sciences Inc., Cambridge,
MA, USA); anti-a2, anti-a4 and anti-a5 (Telios Pharmaceutical
Inc., San Diego, CA, USA); anti-av, anti-b3 and anti-ICAM-1
(Immunotech, Marseille, France); anti-b1 4B4 clone (Coulter
Immunology, Hialeah, FL, USA); anti-CD44 standard form and
variants v4, v6 and v9 (Bender Medsystem, Wien, Austria). The
anti-a2 mAb 5E8 was kindly provided by Dr Bankert (Rosewell
Park Cancer Institute, Buffalo, NY, USA); Dr F Sanchez-Madrid
(Hospital de la Princesa, Madrid, Spain) generously provided the
anti-a4 mAb HP2/1; the anti-a5 Mab16 was a kind gift of Dr KM
Yamada (National Institutes of Health, Bethesda, MD, USA); the rat
anti-a6 mAb GoH3 was generously provided by Dr A Sonnenberg
(Netherlands Red Cross Laboratory, Amsterdam, The Netherlands);
the rat anti-b4 mAb 439-9B was a kind gift of Dr A Sacchi (Regina
Elena Cancer Institute, Rome, Italy); A1A5 anti-b1 mAb was kindly
provided by Dr M Hemler (Dana-Farber Cancer Institute, Boston,
MA, USA); anti-a3 mAb M-KID2 was a kind gift of Dr A
Bartolazzi (Regina Elena Cancer Institute, Rome, Italy). Human
leucocyte antigen (HLA) class I expression was analysed using the
W6/32 mAb, generously provided by Dr G Trinchieri (Wistar
Institute, Philadelphia, PA, USA).
One million cells were stained with the relative primary anti-
body for 30 min at 4°C; after washing, cells were incubated with a
secondary fluorescein isothiocyanate (FITC)-conjugated antibody
for 30 min at 4°C. The relative fluorescence intensity was deter-
mined with a FACScan (Becton Dickinson, Mountain View, CA,
USA) and expressed in arbitrary units on a logarithmic scale.
Tumorigenicity in nu/nu mice
Six-week-old female nu/nu mice of CD1 background (Charles
River Laboratories, Calco, Italy) were maintained under strict
pathogen-free conditions, receiving sterilized pellets and water ad
libitum; their care was in accordance with established international
guidelines. After subcutaneous (s.c.) injection of transduced cells
(106, 5 ´ 106, 107) into the left groin region, mice were monitored
twice weekly to measure tumour growth. Mice with neoplastic
masses > 10 mm were sacrificed for humane reasons. Immuno-
depletion was performed as follows: starting 2 days before tumour
challenge and 4 h after and then at biweekly intervals, mice
received intraperitoneal (i.p.) injections of 0.2 ml of phosphate
buffered saline containing a 1/20 dilution of anti-asialoganglioside
GM1 rabbit antiserum (Wako Chemicals, Dusseldorf, Germany),
100 mg of anti-polymorphonuclear leucocyte mAb (RB6-8C5
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hybridoma, kindly provided by Dr RL Coffman, DNAX Inc., Palo
Alto, CA, USA) or normal rat immunoglobulins purified from
serum or ascitic fluid by passage through an anionic exchange
column (DE 52, Whatman Ltd, Maidstone, UK). Cytofluorimetric
analysis of the blood and spleen cells from mice receiving these
antibodies showed that target leucocytes were selectively
decreased to less than 1/5000 of peripheral blood leucocytes
during treatment. Selective depletion of radiosensitive cells was
obtained by exposing mice to 4.5Gy total body irradiation from a
137Cs source.
RESULTS
Transduction of human bladder carcinoma cell lines
with the IL-2 gene
The bladder carcinoma cell lines RT112 and EJ, derived from two
human transitional cell carcinomas with different histopatholog-
ical grade (G2 and G3 for RT112 and EJ, respectively), were used
as targets of retroviral-mediated IL-2 gene transduction. RT112
and EJ cells exhibit different in vitro growth rate and colony-
forming efficiency, as well as a distinct pattern of integrin
expression and adhesive ability to extracellular matrix (ECM)
components, consistently with their different degree of differentia-
tion (Masters et al, 1986; Nista et al, 1996). After infection and
G418 selection, the productive insertion of the IL-2 gene was eval-
uated by mRNA analysis in RT-PCR. As shown in Figure 1,
neither parental (RT112– and EJ–wt) nor control vector-infected
(RT112– and EJ–neo) cells produced IL-2-specific PCR products,
while IL-2-transduced (RT112– and EJ–IL-2) cells produced a
consistent amount of IL-2 mRNA. Moreover, both RT112–IL-2
and EJ–IL-2 showed consistent release of biologically active IL-2
(194 and 113 IU/106 cells/48h, respectively) that remained practi-
cally unchanged during a period of over 6 months. Both IL-2
mRNA expression and protein production by transfected cells
were stable upon several freeze-thawing cycles and detectable
amounts of IL-2 were released for at least 2 weeks after g-irradia-
tion with up to 10000cGy (data not shown).
Phenotypic and functional characterization of
IL-2-transduced human bladder cancer cell lines
Expression of potentially functional IL-2 receptors (IL-2R), as
well as IL-2-induced functional modifications, has been recently
described on cells of non-lymphoid origin (Velotti et al, 1994;
Yasumura et al, 1994). Although not conclusive, evidence of the
expression of IL-2R a, b, and gchains has been reported also for
RT112 and EJ cell lines (Velotti et al, 1994). These findings raise
the question whether constitutive IL-2 production might modify
the phenotypic and functional characteristics of the transduced
cells; thus, we initially tested parental and IL-2-transduced RT112
and EJ cells for morphology, in vitro growth rate, and [3H]TdR
incorporation (Figure 2). No differences were found in RT112–IL-
2 or EJ–IL-2 as compared to their parental or control vector-trans-
duced counterparts. Even in the presence of absolute or relative
growth factor deprivation, no significant changes in proliferation
rate were seen (Figure 2B).
We then investigated whether IL-2 transduction alters the
pattern of other cytokine genes expressed by RT112 and EJ cells.
As shown in Figure 3, the expression of IL-6, TNF-a, and TGF-b
mRNAs, which are constitutively expressed in both cell lines,
remained unmodified in IL-2-transduced cells in comparison
to control vector-infected cells. Similarly, GM-CSF and IL-4
mRNAs, which were poorly expressed or absent in control vector-
infected cells, were not induced following IL-2 gene transduction.
Immunofluorescence and cytofluorimetric analysis showed no
significant difference in the expression of either HLA class I or
several surface adhesion molecules involved in the control of
tumour–immune cell interactions, as well as tumour growth and
invasion, such as b1 integrins, a6b4, avb3, ICAM-1, CD44 with
its alternatively spliced variants v4, v6, and v9, between
RT112–IL-2 or EJ–IL-2 and their parental or control vector-
transduced counterparts (Figure 4 and Figure 5, respectively).
Tumorigenicity into nu/nu mice of IL-2-transduced
human bladder cancer cell lines
The ability of both RT112 and EJ human bladder cancer cell lines
to grow and form established tumours when injected subcuta-
neously into nu/numice has been previously reported (Masters et
al, 1986). To assess whether IL-2 gene transduction affects their
tumorigenicity, nu/numice were challenged with progressive
doses of either control or IL-2 gene-transduced RT112 or EJ cells.
As shown in Table 1, none of the mice challenged with RT112–IL-
2 or EJ–IL-2 developed palpable tumours over an observation
period of more than 200 days; conversely, the majority of
RT112–neo- and EJ–neo-injected mice developed progressively
growing tumours with latency and tumour growth times inversely
proportional to the number of challenging tumour cells.
To evaluate the importance of the distinct nu/nuhost effector cell
populations potentially involved in the rejection of the IL-2-trans-
duced or control-vector-infected EJ cells, we performed a second
series of experiments in which neutrophils, natural killer (NK) cells
and radiosensitive cells had been depleted in vivo prior to the
tumour challenge. All of the mice challenged with 107 EJ–neo cells
wt
neo
IL-2
wt
neo
IL-2
C
EJ RT112
IL-2 458 bp
334 bp b2-m
Cell line
RT112–wt
RT112–neo
RT112–IL-2
EJ–wt
EJ–neo
EJ–IL-2
IL-2 biological activity
(IU/106 cells/48 h)
<0.05
<0.05
194
<0.05
<0.05
113
Figure 1IL-2 mRNA expression by transduced RT112 and EJ human
bladder cancer cell lines. Parental (wt), control-vector (neo), and IL-2 (IL-2)-
transduced RT112 and EJ cells were analysed for IL-2 mRNA by RT-PCR
(top panel). Total cellular RNA was extracted and reverse transcription, as
well as cDNA amplification, was performed as described in Materials and
methods. RNAs from T-cell blasts obtained by 72-h PHA stimulation of
human PBMC from healthy donors were used as positive controls (C). The
b2-m amplification represents the positive control of cDNA transcription. IL-2
biological activity assay (bottom panel) was performed as described in
Materials and methods. IL-2 values are expressed in IU (as evaluated by
probit computer analysis of the titration curve) and represent the mean of at
least three different determinations over a period of at least 6 monthsIL-2 gene therapy for human bladder cancer 773
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Figure 2 In vitro growth, [3H]TdR uptake, and morphology of IL-2-transduced RT112 and EJ human bladder carcinoma cell lines. Parental (wt), control-vector
(neo), and IL-2 (IL-2)-transduced RT112 and EJ cells were analysed for in vitro growth, [3H]TdR uptake and morphology. In vitro growth was evaluated by
seeding 0.5 ´ 105 cells/well in a 6-well tissue culture plate in standard medium containing 10% FCS and by counting the number of viable cells under light
microscopy every 48 h for up to 9 days (A). Proliferative ability was evaluated by measuring [3H]TdR uptake after 96 h in different culture conditions: 96 h in
standard medium containing 10% FCS, 96 h in medium containing 0.5% BSA, or 48 h in medium containing 0.5% BSA followed by 48 h in medium containing
5% FCS. Cells were then pulsed with [3H]TdR for 18 h, harvested, and the [3H]TdR uptake was measured by liquid scintillation counting. Experiments were
performed in triplicates and results are expressed as average cpm ± SE (B). Results are representative of one out of four independent experiments. Morphology
was evaluated by culturing the cells on tissue-culture-treated glass slides; cells were then fixed and stained with haematoxylin and eosin, and microphotographs
were taken at ´ 400 (C)774 M Milella et al
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developed progressively growing tumours, but both latency and
tumour growth times were significantly shorter in polymorpho-
nuclear (PMN) and NK cell-depleted animals than in untreated or
irradiated mice (Table 2). With regard to EJ–IL-2 cells, the tumour
challenge was completely rejected by all mice that remained
tumour free for up to 200 days regardless of the immunosuppres-
sive treatment received, although the maximum tumour diameter
reached before rejection was significantly higher in mice deprived
of PMN cells and in those receiving irradiation (Table 3).
DISCUSSION
In this study we provide evidence that the human IL-2 gene can be
stably and productively transduced into human bladder cancer
cells without modifying their phenotypic and functional features.
The constitutive IL-2 release abrogates human transitional bladder
cancer ability to grow into nu/nu mice, by eliciting in the immuno-
suppressed host an anti-tumour activity based on different effector
cell populations.
Retroviral vector-mediated stable and productive insertion of
the IL-2 gene into human cancer cells has been documented for
several tumours, such as melanoma, renal cell carcinoma, myeloid
and lymphoid leukaemic cells, colon carcinoma, and lung carci-
noma (Gansbacher et al, 1992; Gastl et al, 1992; Cignetti et al,
1994; Guarini et al, 1996; Stein et al, 1996). With regard to
urothelial tumours, adenoviral-mediated gene transfer of both the
reporter gene luciferase and a truncated form of the oncosuppres-
sive gene RB-1 have been reported (Bass et al, 1995; Xu et al,
1996). The present study provides the first evidence that human
transitional cell carcinoma of the bladder can be engineered to
constitutively secrete biologically active human IL-2 by using
retroviral vectors. In many instances, living and proliferating
cancer cells appear to be more efficient as a vaccine than those
whose proliferative ability is blocked by irradiation or mitomycin
C treatment. Nevertheless, the possibility to introduce undesired
variables in engineered cancer cell behaviour is still of major
concern in view of their clinical use, precluding the development
of live cancer vaccines. With regard to bladder carcinoma, the
possibility that certain cytokines, namely IL-2 and IL-6, may act as
autocrine growth factors has been reported (Hawkyard et al, 1993;
Yasumura et al, 1994; Okamoto et al, 1997). Moreover, a previous
study from our group (Velotti et al, 1994) has shown that mRNA
for the a chain of the IL-2R is expressed by both RT112 and EJ
cell lines, whereas mRNA for the g chain is clearly evident in the
RT112 cell line and detectable only after a long exposure in the
EJ cell line; with regard to the IL-2R b chain, both cell lines
positively stain with anti-p70/75 mAbs, although neither express
specific mRNA sequences, as assessed by PCR. Furthermore,
recent results from our group indicate that no modulation of IL-2R
expression, at both the mRNA and protein level, is observed in
IL-2 gene-transduced RT112 and EJ cells, as compared to their
control-vector-transfected or parental counterparts (F Velotti,
unpublished observations). The extensive functional and pheno-
typic characterization performed in the present study suggests that
transduction of the human bladder cancer cell lines RT112 and EJ
with the IL-2 gene does not affect their morphology, growth rate or
proliferation, nor does it modify the pattern of other cytokine gene
or membrane adhesion receptor, as well as HLA class I expression.
These results are in agreement with previous studies of IL-2 gene
transfer in human renal carcinoma, small cell lung carcinoma and
leukaemia cells (Gastl et al, 1992; Cignetti et al, 1994; Meazza et
al, 1996). However, some alterations in tumour cell behaviour and
phenotype following IL-2 gene transduction in human cancer cells
have been recently described. IL-2-transduced renal carcinoma
cell lines exhibit an enhanced ICAM-1 and a reduced CD44
expression, as well as a decreased adhesiveness to ECM compo-
nents, as compared with their parental counterparts (Hathorn et al,
1994); TGF-b1 down-modulation has been documented in both
renal cell carcinoma and lung adenocarcinoma following IL-2
gene transfer (Hathorn et al, 1994; Guarini et al, 1996); decreased
mdr-1 expression and increased chemosensitivity has been shown
in IL-2 gene-transduced human colon carcinoma cell lines
(Stein et al, 1996).
As reported for several IL-2-transduced human tumours of
different histologic origin (Gansbacher et al, 1992; Gastl et al,
1992; Cignetti et al, 1994; Guarini et al, 1996), bladder carcinoma
cells engineered to release IL-2 lose their tumorigenic ability in
immunosuppressed mice. Our results using selective immuno-
depletion techniques suggest that multiple cell populations are
involved in the rejection of IL-2-releasing cells, among which a
prominent role appears to be played by PMN and other radiosensi-
tive cells. Polymorphonuclear granulocyte recruitment and activa-
tion has been implicated as a pivotal effector mechanism during
rejection responses elicited by IL-2-engineered cancer cells
(Cavallo et al, 1992; Colombo et al, 1992; Meazza et al, 1996;
Musiani et al, 1997). In both immunocompetent mice challenged
with an IL-2-secreting syngeneic mammary adenocarcinoma
(Cavallo et al, 1992) and athymic mice challenged with an IL-2
gene-transduced human small cell lung carcinoma (Meazza et al,
1996), the appearance of a neutrophil infiltrate at the periphery of
the tumour cell aggregate is an early (days 3 and 2 after challenge,
respectively) event in the rejection process, suggesting that the
neo
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C
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Figure 3 Cytokine mRNA expression by IL-2-transduced RT112 and EJ
human bladder carcinoma cell lines. Control-vector (neo) and IL-2 (IL-2)-
transduced RT112 and EJ cells were analysed for cytokine mRNAs by RT-
PCR. Total cellular RNA was extracted and reverse transcription, as well as
cDNA amplification, was performed as described in Materials and methods.
RNAs from T-cell blasts obtained by 72 h-PHA stimulation of human PBMC
from healthy donors (IL-4, TNFa, TGFb, and GM-CSF) or RPMI 8866 EBV+ B
lymphoblastoid cell line (IL-6) were used as positive controls (C). The b2-m
amplification represents the positive control of cDNA transcriptionIL-2 gene therapy for human bladder cancer 775
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presence of tumour neovascularization is not required. In the
former model, moreover, the extent and rapidity of neutrophil
recruitment is proportional to the amount of IL-2 released from the
transduced cells. IL-2 may recruit and activate PMN cells either
directly through the interaction with its receptor (Djeu et al, 1993;
Liu et al, 1994), leading to cytokine secretion and stimulation of
tumoricidal activity (Wei et al, 1993, 1994; Girard et al, 1995;
Pericle et al, 1996), or through its action on T- and NK cells,
leading to a cascade of secondary neutrophil-activating cytokines
and chemokines, such as IL-8 and TNF-a.
The subsequent complete rejection of EJ–IL-2 cells by PMN-
depleted and irradiated nu/nu mice suggests the emergence of
alternative effector mechanisms, mediated by NK cells and mono-
cyte/macrophages. Both NK cells and monocyte/macrophages
have indeed been implicated in the rejection of IL-2-secreting
cancer cells by mice lacking functional T- and B-cells (Alosco et
al, 1993; Hara et al, 1995). Moreover, as shown in Table 2, NK
cells, as well as radioresistant populations, play a relevant role in
the growth control of xenografted EJ–neo cells.
The recent work by Meazza and colleagues (Meazza et al,
1996) on IL-2-transduced small cell lung carcinoma suggests that,
in addition to the activation of macrophages (Verstovsek et al,
1992), IL-2 may exert its effects by altering tumour vasculariza-
tion either by a direct action on endothelial cells (Hicks et al,
1991), or by promoting a cascade of secondary cytokines (such as
IL-1, TNF-a, IL-8), which in turn mediate further vascular and
tissue damage, and amplify neutrophil recruitment. Although the
role of such mechanisms in the rejection of IL-2 gene-transduced
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Figure 4 Cytofluorimetric analysis of HLA class I and adhesion molecule expression on control-vector or IL-2-transfected RT112 cells. RT112–neo (black
profile) and RT112–IL-2 (green profile) were stained with specific mAbs (see Materials and methods) and a fluorescein-conjugated secondary Ab. The red area
represents negative control obtained by staining cells with an isotype-matched irrelevant mAb776 M Milella et al
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bladder cancer cells has not been explored in the present study, an
even more interesting support to their potential relevance in this
tumour model comes from our earlier experience with intra-
arterial or intravesical rIL-2 treatment in patients with superficial
transitional cell carcinoma of the bladder (Tubaro et al, 1991,
1995; Velotti et al, 1991a, 1991b). In these clinical trials we
observed a significant increase in the inflammatory response at
the tumour site, with evident infiltration of tumour stroma and
neoplastic epithelium by activated (CD25+/HLA-DR+) T-cells,
macrophages and both eosinophil and PMN. Increase in tumour-
associated inflammatory response appeared to be a necessary step
for T-cell activation and IFN-g release, which in turn induced IL-
1a, IL-1b and TNF-a production from macrophages. Moreover,
increase of tumour-infiltrating leucocytes and their cytokine
secretion were associated with the expression of adhesion
molecules (ICAM-1, VCAM-1 and E-selectin) on the vascular
endothelium.
Unfortunately, studies with human tumours in nu/nu mice do
not allow for evaluating the ability of cytokine-transduced cells to
elicit a T-cell response. In vitro experiments with IL-2-engineered
human melanoma and lung carcinoma cells cocultured with allo-
geneic or autologous peripheral blood mononuclear cells (PBMC)
have shown that IL-2 released by the engineered cells is capable of
supporting CD3+ and, to a lesser extent, CD56+ cell viability, and
to stimulate both promiscuous and specific cytotoxic activity
(Guarini et al, 1995, 1997). Preliminary results with RT112– and
EJ–IL-2 cells cocultured with PBMC from partially HLA-matched
donors suggest that they are capable of stimulating T-cell growth
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Figure 5 Cytofluorimetric analysis of HLA class I and adhesion molecule expression on control-vector or IL-2-transfected EJ cells. EJ–neo (blue profile) and
EJ–IL-2 (green profile) were stained with specific mAbs (see Materials and methods) and a fluorescein-conjugated secondary Ab. The red area represents
negative control obtained by staining cells with an isotype-matched irrelevant mAb
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and lymphokine activated killer-like cytotoxicity (M Milella,
unpublished results). Moreover, the recent work from one of us
(Guarini et al, 1997) provides evidence that IL-2 gene transfer
can overcome tumour-induced immunosuppression much more
efficiently than rIL-2.
Although further studies are needed, especially in an attempt to
identify molecular targets for a specific immune intervention
against human transitional cell carcinoma of the bladder, the find-
ings reported in the present study offer a valuable support to the
development of immunization strategies employing bladder carci-
noma cells, ex vivo transduced with the IL-2 gene.
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Table 1 Tumorigenicity in nu/nu mice of the IL-2-transduced human bladder carcinoma cell lines
RT112 and EJ
Challenge Latency timeb Tumour growth
Cell line (no. of cells) Tumour takea (days) timec (days)
RT112–neo 1 ´ 106 7/8 24.2 ± 3.8 44.9 ± 4.4
5 ´ 106 7/8 17.9 ± 3.1 30.8 ± 3.8
10 ´ 106 8/8 18.3 ± 4.2 29.3 ± 4.1
RT112–IL-2 1 ´ 106 0/8 – > 200
5 ´ 106 0/8 – > 200
10 ´ 106 0/8 – > 200
EJ–neo 1 ´ 106 8/8 18.2 ± 3.7 40.3 ± 9.1
5 ´ 106 8/8 15.7 ± 4.1 35.9 ± 5.3
10 ´ 106 8/8 14.4 ± 4.2 28.6 ± 6.8
EJ–IL-2 1 ´ 106 0/8 – > 200
5 ´ 106 0/8 – > 200
10 ´ 106 0/8 – > 200
aTumour take: No. of mice developing a palpable tumour/No. of mice challenged. Data from two
separate experiments have been cumulated. bLatency time: Days from the challenge to the
development of a tumour with a mean diameter of 3 mm (average ± SE). cTumour growth time:
Days from the challenge to the development of a tumour with a mean diameter of 10 mm
(average ± SE).
Table 2 Tumorigenicity of EJ–neo cells in immunodepleted nu/nu mice
Treatment Tumour takea Latency timeb Pc Tumour growth P
(days) timed (days)
None 12/12 15.3 ± 4.7 59.8 ± 7.6
a- PMN 10/10 10.1 ± 1.7 0.003 51.0 ± 3.8 0.004
a-asialo GM1 10/10 09.9 ± 1.7 0.002 45.5 ± 6.9 < 0.001
Irradiation 10/10 13.8 ± 1.6 NS 53.1 ± 9.8 0.088
Irradiation +
a-asialo GM1 10/10 10.3 ± 1.8 0.004 46.8 ± 5.2 < 0.001
Mice were treated as described in Materials and methods and challenged s.c. with 107 EJ–neo cells. aTumour take: No.
of mice developing a palpable tumour/No. of mice challenged. Data from two separate experiments have been
cumulated. bLatency time: Days from the challenge to the development of a tumour with a mean diameter of 3 mm
(average ± SE). cP-value is calculated by comparing mean latency or tumour growth times between each treatment
group and untreated controls by ‘two-tailed student’s t-test’. dTumour growth time: Days from the challenge to the
development of a tumour with a mean diameter of 10 mm (average ± SE).
Table 3 Maximum tumour diameter reached by EJ–IL-2 cells before rejection
in immunodepleted nu/nu mice
Tumour size (mm)a
Treatment Distribution Mean ± SE Pb
None 0, 0, 0, 0, 1, 1, 1, 1, 1, 2 0.7 ± 0.7
a-PMN 1, 1, 2, 2, 2, 2, 2, 2, 3, 3 2.0 ± 0.7 < 0.001
a-asialo GM1 0, 0, 0, 1, 1, 1, 1, 2, 2, 2 1.0 ± 0.8 NS
Irradiation 1, 1, 2, 2, 2, 2, 2, 2, 3, 3 2.0 ± 0.7 < 0.001
Irradiation +
a-asialo GM1 1, 1, 1, 2, 2, 2, 2, 2, 2, 3 1.8 ± 0.6 0.001
aMice were treated as described in Materials and methods and challenged
s.c. with 107 EJ–IL-2 cells. Maximal tumour growth was reached by day 11
after challenge. All mice completely rejected the tumour by day 34 and
remained tumour-free for up to 200 days. Data from two separate
experiments have been cumulated. bP-value is calculated by comparing mean
tumour size between each treatment group and untreated controls by ‘two-
tailed Student’s t-test’.778 M Milella et al
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